

IN THE CLAIMS

1. (original) An immunogenic composition comprising a combination of GBS polypeptides, said combination consisting of two, three, four or five polypeptides, wherein each polypeptide is encoded by a GBS polynucleotide sequence which is homologous to a polynucleotide sequence of both GAS and *Streptococcus pneumoniae*.

2. (currently amended) The immunogenic composition of claim 1, wherein said GBS polypeptides are encoded by GBS polynucleotide sequences selected from SEQ ID NOS:17-33, 34-44, 45-61, 62-72, 73-122, 157-167, 180-190, 202-210, 285-295, 385-395, 407-417, 463-474, 508-518, 597-607, 619-629, 641-651, 685-695, 752-762, 823-833, 886-896, 908-918, 930-940, 980-990, 1022-1032, 1132-1142, 1182-1192, 1226-1236, 1248-1258, and 1311-1321 GBS Subset 1.

3. (original) An immunogenic composition comprising a combination of GBS polypeptides, said combination consisting of two, three, four or five polypeptides, wherein each polypeptide is encoded by a GBS polynucleotide sequence which is homologous to a polynucleotide sequence of GAS.

4. (currently amended) The immunogenic composition of claim 3, wherein said GBS polypeptides are encoded by GBS polynucleotide sequences selected from SEQ ID NOS:1-16, 135-145, 223-231, 307-316, 349-357, 430-440, 486-496, 574-584, 729-739, 802-812, 958-968, 1002-1011, 1044-1054, 1066-1076, 1204-1214, and 1271-1281 GBS Subset 2.

5. (original) An immunogenic composition comprising a combination of GBS polypeptides, said combination consisting of two, three, four or five polypeptides, wherein each polypeptide is encoded by a GBS polynucleotide sequence which is homologous to a polynucleotide sequence of *Streptococcus pneumoniae*.

6. (currently amended) The immunogenic composition of claim 5, wherein said GBS polypeptides are encoded by GBS polynucleotide sequences selected from SEQ ID NOS:327-337, 367-375, 663-673, and 780-790 GBS Subset 3.

7. (original) An immunogenic composition comprising a combination of GBS polypeptides, said combination consisting of two, three, four or five polypeptides, wherein each polypeptide is encoded by a GBS serotype polynucleotide sequence which is homologous to at least one other GBS serotype.

8. (original) The immunogenic composition of claim 2, wherein one or more of the GBS polypeptides are encoded by GBS serotype polynucleotide sequences which are homologous to at least one other GBS serotype.

9. (original) An immunogenic composition comprising a fusion protein, wherein said fusion protein comprises a first polypeptide sequence which is encoded by a GBS serotype polynucleotide which is conserved across one or more GBS serotypes.

10. (currently amended) A polynucleotide sequence, or a fragment comprising at least 10 contiguous polynucleotides, selected from SEQ ID NOS:1-122, 135-145, 157-167, 180-190, 202-210, 223-231, 241-251, 263-273, 285-295, 307-316, 327-337, 349-357, 367-375, 385-395, 407-417, 430-440, 452-457, 463-474, 486-496, 508-518, 530-540, 558-565, 574-584, 597-607, 619-629, 641-651, 663-673, 685-695, 707-717, 729-739, 752-762, 774-776, 780-790, 802-812, 823-833, 846-854, 864-874, 886-896, 908-918, 930-940, 952-954, 958-968, 980-990, 1002-1011, 1022-1032, 1044-1054, 1066-1076, 1088-1098, 1110-1120, 1132-1142, 1154-1156, 1182-1192, 1204-1214, 1226-1236, 1248-1258, 1271-1281, 1293-1301, 1311-1321 1333-1343 the sequences set forth on Tables 13-31 and 40-89.

11. (original) The polynucleotide fragment of claim 10, wherein said fragment is derived from a GBS serotype polynucleotide sequence and is homologous to at least one additional GBS serotype polynucleotide sequence.

12. (original) The immunogenic composition of claim 4, wherein one or more of the GBS polypeptides are encoded by GBS serotype polynucleotide sequences which are homologous to at least one other GBS serotype.

13. (original) The immunogenic composition of claim 6, wherein one or more of the GBS polypeptides are encoded by GBS serotype polynucleotide sequences which are homologous to at least one other GBS serotype.